Patents by Inventor Kenya Shitara
Kenya Shitara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
MONOCLONAL ANTIBODY CAPABLE OF BINDING TO HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR
Publication number: 20100184958Abstract: Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.Type: ApplicationFiled: December 8, 2008Publication date: July 22, 2010Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: EISUKE MEKADA, RYO IWAMOTO, SHINGO MIYAMOTO, KENYA SHITARA, AKIKO FURUYA, KAZUYASU NAKAMURA, KUMIKO TAKAHASHI, HIROSHI ANDO, KAZUHIRO MASUDA, YUKA SASAKI -
Publication number: 20100150917Abstract: The present invention relates to the method for depleting in vivo regulatory T cell, the method for suppressing IL-10 producing activity of regulatory T cell, the method for treating diseases in which pathologic conditions are deteriorated by regulatory T cell and the method for enhancing tumor immunity which comprises administering to a patient a monoclonal antibody which specifically binds to human CC chemokine 4 (CCR4) or the antibody fragment thereof.Type: ApplicationFiled: October 5, 2009Publication date: June 17, 2010Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Ryuzo UEDA, Kenya Shitara, Shiro Akinaga, Rinpei Niwa, Masamichi Koike
-
Publication number: 20100092997Abstract: A method for enhancing a binding activity of an antibody composition to Fc? receptor IIIa, which comprises modifying a complex N-glycoside-linked sugar chain which is bound to the Fc region of an antibody molecule; a method for enhancing an antibody-dependent cell-mediated cytotoxic activity of an antibody composition; a process for producing an antibody composition having an enhanced binding activity to Fc? receptor IIIa; a method for detecting the ratio of a sugar chain in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chain among total complex N-glycoside-linked sugar chains bound to the Fc region in an antibody composition; an Fc fusion protein composition produced by using a cell resistant to a lectin which recognizes a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through ?-bond in a complex N-glycoside-linked sugar chain; and a process for producing the same.Type: ApplicationFiled: August 28, 2009Publication date: April 15, 2010Applicant: KYOWA HAKKO KIRIN CO., LTDInventors: Kazuyasu Nakamura, Kenya Shitara
-
Patent number: 7691568Abstract: A medicament for treating a patient who cannot be cured with a medicament comprising as an active ingredient an antibody composition produced by a cell unresistant to a lectin which recognizes a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through ?-bond in a complex N-glycoside-linked sugar chain, which comprises as an active ingredient an antibody composition produced by a cell resistant to a lectin which recognizes a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through ?-bond in a complex N-glycoside-linked sugar chain, and a method for screening the patient by using the medicament.Type: GrantFiled: April 9, 2003Date of Patent: April 6, 2010Assignee: Kyowa Hakko Kirin Co., LtdInventors: Rinpei Niwa, Kenya Shitara
-
Patent number: 7666418Abstract: A recombinant antibody or the antibody fragment thereof which specifically reacts with an extracellular domain of human CCR4; a DNA which encodes the recombinant antibody or the antibody fragment thereof; a method for producing the recombinant antibody or the antibody fragment thereof; a method for immunologically detecting CCR4, a method for immunologically detecting a cell which expressed CCR4 on the cell surface, a method for depleting a cell which expresses CCR4 on the cell surface, and a method for inhibiting production of Th2 cytokine, which comprise using the recombinant antibody according or antibody fragment thereof; a therapeutic or diagnostic agent for Th2-mediated immune diseases; and a therapeutic or diagnostic agent for a blood cancer.Type: GrantFiled: March 31, 2005Date of Patent: February 23, 2010Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Kenya Shitara, Nobuo Hanai, Emi Shoji, Mikiko Sakurada, Akiko Furuya, Kazuyasu Nakamura, Rinpei Niwa, Kenji Shibata, Motoo Yamasaki
-
Patent number: 7615214Abstract: The present invention provides an antibody or peptide which immunologically reacts with human VEGF receptor Flt-1 and cells in which human VEGF receptor Flt-1 is expressed on the cell surface and an antibody or peptide which inhibits binding of human VEGF to human VEGF receptor Flt-1. It also provides a means for the diagnosis or treatment of diseases in which their morbid states progress by abnormal angiogenesis, such as proliferation or metastasis of solid tumors, arthritis in rheumatoid arthritis, diabetic retinopathy, retinopathy of prematurity, psoriasis, and the like.Type: GrantFiled: October 17, 2005Date of Patent: November 10, 2009Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Kenya Shitara, Mikito Ito, Nobuo Hanai, Yoko Kawada, Kazuyasu Nakamura, Masabumi Shibuya
-
Patent number: 7615215Abstract: The present invention provides an antibody or peptide which immunologically reacts with human VEGF receptor Flt-1 and cells in which human VEGF receptor Flt-1 is expressed on the cell surface and an antibody or peptide which inhibits binding of human VEGF to human VEGF receptor Flt-1. It also provides a means for the diagnosis or treatment of diseases in which their morbid states progress by abnormal angiogenesis, such as proliferation or metastasis of solid tumors, arthritis in rheumatoid arthritis, diabetic retinopathy, retinopathy of prematurity, psoriasis, and the like.Type: GrantFiled: March 21, 2006Date of Patent: November 10, 2009Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Kenya Shitara, Mikito Ito, Nobuo Hanai, Yoko Kawada, Kazuyasu Nakamura, Masabumi Shibuya
-
Publication number: 20090258007Abstract: The present invention provides an antibody which specifically recognizes three-dimensional structure of an extracellular region of a polypeptide encoded by PERP (p53 apoptosis effector related to PMP-22) gene and binds to the extracellular region. The antibody of the present invention is useful for treatment of various diseases which highly expresses a polypeptide encoded by the PERP gene. Also, a polypeptide encoded by the PERP gene or a cell expressing the polypeptide can be specifically detected by an immunological method using the antibody, so that the antibody is useful for diagnosis of various diseases related to PERP.Type: ApplicationFiled: June 7, 2005Publication date: October 15, 2009Applicants: KYOWA HAKKO KOGYO CO., LTD., President National Cancer CenterInventors: Atsushi Ochiai, Norihiko Shiraishi, Yoko Kato, Toshio Ota, Susumu Sekine, Kenya Shitara, Akiko Furuya, So Ohta, Emi Hosaka, Yuka Sasaki
-
Publication number: 20090227012Abstract: A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.Type: ApplicationFiled: February 27, 2009Publication date: September 10, 2009Applicant: KYOWA HAKKO KOGYO CO., LTD.Inventors: Kenya SHITARA, Kazuyasu Nakamura, Emi Hosaka, Akiko Tanaka, Masamichi Koike
-
Publication number: 20090226399Abstract: In order to obtain high therapeutic effects in treating malignant tumors, particularly melanoma, a new therapeutic method having less side effects, or a new therapeutic method which can provide further high therapeutic effects at conventional doses of agents has been desired. An object of the present invention is to provide a medicament which can provide higher therapeutic effects than any one of a gene recombinant antibody against ganglioside GD3 or the antibody fragment thereof alone, and a substance which activates an immunocomponent cell and a substance having an antitumor activity alone, by combining a gene recombinant antibody against ganglioside GD3 or the antibody fragment thereof with at least one of a substance which activates an immunocomponent cell and a substance having an antitumor activity. Also, the medicament is expected to relieve side effects which were problems in the case of administration of individual single agents.Type: ApplicationFiled: April 8, 2009Publication date: September 10, 2009Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Kenya Shitara, Rinpei Niwa, Junji Kanazawa, Masao Asada
-
Patent number: 7504104Abstract: A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.Type: GrantFiled: August 30, 2002Date of Patent: March 17, 2009Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Kenya Shitara, Kazuyasu Nakamura, Emi Hosaka, Akiko Tanaka, Masamichi Koike
-
Patent number: 7498415Abstract: It is demanded that pharmaceutical agents for therapeutic treatment of diseases such as cancer, acromegaly and diabetic complications, of which IGF is involved in the progress of the conditions. The present invention provides a recombinant antibody or an antibody fragment thereof which specifically binds to human insulin-like growth factor-I (hereinafter referred to as hIGF-I) and human insulin-like growth factor-II (hereinafter referred to as hIGF-II) to inhibit the biological activities of human IGF-I and human IGF-II, a transformant producing the antibody or the antibody fragment thereof, a process for producing the antibody or the antibody fragment thereof, and a medicament comprising the antibody or the antibody fragment thereof as the active ingredient therein.Type: GrantFiled: September 24, 2004Date of Patent: March 3, 2009Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Kenya Shitara, Kazuyasu Nakamura, Yuji Ohki
-
Publication number: 20090028877Abstract: An anti-ganglioside GM2 antibody composition having enhanced effector function which is useful as a medicament has been desired. The present invention provides an antibody composition comprising an antibody molecule which specifically binds to ganglioside GM2 and has complex type N-glycoside-linked sugar chains in the Fc region, wherein the complex type N-glycoside-linked sugar chains have a structure in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chains; a transformant which produces the antibody composition; a process for producing the antibody composition; and a pharmaceutical composition comprising the antibody composition.Type: ApplicationFiled: October 8, 2004Publication date: January 29, 2009Inventors: Shigeru Iida, Mitsuo Satoh, Miho Takabe, Masako Wakitani, Kazuhisa Uchida, Rinpei Niwa, Kenya Shitara
-
Patent number: 7479371Abstract: The present invention relates to a method for diagnosing leukemia, pre-leukemia or aleukemic malignant blood diseases, a method of discriminating leukemia from pre-leukemia or aleukemic malignant blood diseases, a method of discriminating aplastic anemia from myelodysplastic syndrome, a method of diagnosing delayed engraftment of the hematopoietic stem cells after transplantation of the hematopoietic stem cells, and a method of diagnosing the graft versus host disease, each of said methods comprising quantifying stem cell growth factor (SCGF). The present invention also makes it possible to provide an agent for diagnosing leukemia, pre-leukemia or aleukemic malignant blood diseases and an agent for diagnosing delayed engraftment of the hematopoietic stem cells after transplantation of the hematopoietic stem cells or an agent for diagnosing graft versus host disease (GVHD), each containing as an active ingredient an antibody reacting with stem cell growth factor (SCGF).Type: GrantFiled: April 9, 2003Date of Patent: January 20, 2009Assignees: Tokai University, Kyowa Hakko Kogyo Co., Ltd., Kyowa Medex Co., Ltd.Inventors: Kiyoshi Ando, Tomomitsu Hotta, Chie Ito, Hidenao Sato, Akiko Furuya, Kenya Shitara, Seiji Sugimoto, Hiroaki Kohno
-
Publication number: 20090004186Abstract: The present invention relates to a recombinant antibody composition which is a human IgG1 antibody, comprises a CH2 domain in which amino acids at positions 276 and 339 indicated by the EU index as in Kabat, et al. are replaced by other amino acids and has more improved complement-dependent cytotoxic activity than an antibody comprising a CH2 domain before the amino acids are replaced; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the DNA into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.Type: ApplicationFiled: January 24, 2008Publication date: January 1, 2009Applicant: KYOWA HAKKO KOGYO CO., LTD.Inventors: Kenya SHITARA, Rinpei NIWA, Akito NATSUME
-
Patent number: 7438911Abstract: For the effective treatment of diseases such as cancer in which hIGF participates, there have been desired to be developed antibodies which strongly bind to both factors hIGF-I and hIGF-II and inhibit their functions and fragments of these antibodies. The present invention provides antibodies which have the ability to specifically bind to human IGF-I and IGF-II to thereby inhibit the functions of human IGF-I and IGF-II and have binding activity with a binding constant of 5×109 M?1 or more measured with a biosensor BIACORE. In addition, the present invention provides diagnostics, preventives and remedies for an hIGF-mediated disease and a disease showing pathological progressing due to abnormally promoted hIGF production, which use said antibodies.Type: GrantFiled: April 30, 2003Date of Patent: October 21, 2008Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Kenya Shitara, Kazuyasu Nakamura, Akiko Furuya, Rinpei Niwa, Yuji Ohki, Nobuo Hanai
-
Publication number: 20080241884Abstract: A fusion protein composition of an antibody Fc region which is useful as a medicament in which effector function is improved is desired. The present invention provides a fusion protein composition comprising a fusion protein molecule of an antibody Fc region having complex type N-glycoside-linked sugar chains in the Fc region, wherein the complex type N-glycoside-linked sugar chains have a structure in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chains; a transformant producing the fusion protein composition; a process for producing the fusion protein composition; and a medicament comprising the fusion protein composition.Type: ApplicationFiled: October 8, 2004Publication date: October 2, 2008Inventors: Kenya Shitara, Emi Hosaka, Akito Natsume, Masako Wakitani, Kazuhisa Uchida, Mitsuo Satoh, Naoko Ohnuki, Kazuyasu Nakamura
-
Publication number: 20080213266Abstract: The present invention provides an antibody composition comprising an antibody molecule which specifically binds to human CC chemokine receptor 4 (CCR4) and has complex type N-glycoside-linked sugar chains in the Fc region, wherein the complex type N-glycoside-linked sugar chains have a structure in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chains; a transformant which produces the antibody composition; a process for producing the antibody composition; and a pharmaceutical composition comprising the antibody composition.Type: ApplicationFiled: January 4, 2008Publication date: September 4, 2008Inventors: Shigeru Iida, Mitsuo Satoh, Miho Urakubo, Masako Wakitani, Kazuhisa Uchida, Rinpei Niwa, Kenya Shitara
-
Publication number: 20080187529Abstract: The present invention provides an antibody or peptide which immunologically reacts with human VEGF receptor Flt-1 and cells in which human VEGF receptor Flt-1 is expressed on the cell surface and an antibody or peptide which inhibits binding of human VEGF to human VEGF receptor Flt-1. It also provides a means for the diagnosis or treatment of diseases in which their morbid states progress by abnormal angiogenesis, such as proliferation or metastasis of solid tumors, arthritis A in rheumatoid arthritis, diabetic retinopathy, retinopathy of prematurity, psoriasis, and the like.Type: ApplicationFiled: March 21, 2006Publication date: August 7, 2008Applicant: KYOWA HAKKO KOGYO CO., LTD.Inventors: Kenya Shitara, Mikito Ito, Nobuo Hanai, Yoko Kawada, Kazuyasu Nakamura, Masabumi shibuya
-
Patent number: 7404953Abstract: The present invention provides an apoptosis inducer and a therapeutic agent for eosinophilic diseases which comprises, as an active ingredient, an antibody which reacts specifically with eosinophils and induces apoptosis of eosinophils; and a method for inducing eosinophil apoptosis using the antibody, and a method for specifically reducing or removing eosinophils in peripheral blood or tissues using the antibody.Type: GrantFiled: February 15, 2001Date of Patent: July 29, 2008Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Emi Hosaka, Kazuyasu Nakamura, Masamichi Koike, Kenya Shitara, Nobuo Hanai